{"product_id":"can-we-slow-down-aging-inside-the-push-to-extend-healthspan","title":"Can We Slow Down Aging? Inside the Push to Extend \"Healthspan\"","description":"\u003cp\u003eTwo groups of leading aging researchers argue that modern medicine's strategy of treating diseases one at a time — heart failure today, cancer tomorrow, arthritis next year — is failing older adults, and that we should instead target the aging process itself. Evidence from animal studies, human genetics, and exceptionally long-lived people shows that aging is not fixed; it can be slowed. The authors call for new functional tests in animals, better collaboration between laboratory and clinical researchers, and a fundamental shift in how aging research is funded and organized. This article translates their two-part commentary from \u003cem\u003eNature\u003c\/em\u003e into plain language for patients and families.\u003c\/p\u003e\n\n\u003ch1\u003eCan We Slow Down Aging? Inside the Push to Extend \"Healthspan\"\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#the-problem\"\u003eThe Problem: Aging Comes as a Package\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#animal-studies\"\u003eWhat Animal Studies Have Taught Us\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#malleable\"\u003eWhy Aging Is Malleable: Evidence from Humans\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#drugs-diets\"\u003eDrugs and Diets on the Horizon\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#demographics\"\u003eThe Demographic Challenge Ahead\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#funding\"\u003eA Major Roadblock: Funding and Focus\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#functional-tests\"\u003eHow We Measure Aging: The Power of Simple Tests\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#the-gap\"\u003eThe Gap: What's Missing in Animal Studies\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#better-tools\"\u003eBuilding Better Tools to Track Aging\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#roadmap\"\u003eRecommendations: A Roadmap Forward\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#for-patients\"\u003eWhat This Means for Patients Today\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations and Open Questions\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAging is malleable, not fixed, according to animal and human evidence.\u003c\/li\u003e\n\u003cli\u003eOver 70% of adults over 65 have two or more chronic conditions; aging is a common risk factor.\u003c\/li\u003e\n\u003cli\u003eSimple tests like grip strength and walking speed predict disability and survival.\u003c\/li\u003e\n\u003cli\u003eRapamycin, metformin, and resveratrol extend lifespan in animals but are unproven for humans.\u003c\/li\u003e\n\u003cli\u003ePrevention should start earlier in life; diet and exercise remain effective for healthy aging.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\u003cp\u003eIn July 2014, the prestigious journal \u003cem\u003eNature\u003c\/em\u003e published a special commentary asking a bold question: What if we stopped trying to cure individual diseases of old age — and instead targeted aging itself?\u003c\/p\u003e\n\u003cp\u003eThe commentary brings together two teams of scientists. The first, led by Dr. Luigi Fontana (Washington University in St. Louis and Brescia University, Italy), Dr. Brian K. Kennedy (Buck Institute for Research on Aging), and Dr. Valter D. Longo (University of Southern California), argues that we must \"prepare for human testing\" of anti-aging interventions. The second, led by Dr. Douglas Seals (University of Colorado Boulder) and Dr. Simon Melov (Buck Institute), explains why we need to \"track function in ageing animals\" to bridge the gap between laboratory discoveries and real patient care.\u003c\/p\u003e\n\u003cp\u003eThe stakes are enormous. The authors project that by 2050, the number of people over 80 will triple globally — and the number over 60 will be five times what it was in 1950. As Dr. Fontana's team puts it, \"These demographics could come at great cost to individuals and economies.\"\u003c\/p\u003e\n\n\u003ch2 id=\"the-problem\"\u003eThe Problem: Aging Comes as a Package\u003c\/h2\u003e\n\u003cp\u003eHere's the core insight: \u003cstrong\u003ethe problems of old age come as a package.\u003c\/strong\u003e More than 70% of people over 65 have two or more chronic conditions at the same time — conditions like:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eArthritis\u003c\/li\u003e\n  \u003cli\u003eDiabetes\u003c\/li\u003e\n  \u003cli\u003eCancer\u003c\/li\u003e\n  \u003cli\u003eHeart disease\u003c\/li\u003e\n  \u003cli\u003eStroke\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCurrent medicine treats these one at a time. A patient might see a cardiologist for heart failure, an oncologist for cancer, and an endocrinologist for diabetes — as if these were unrelated problems.\u003c\/p\u003e\n\u003cp\u003eBut the evidence suggests otherwise. Studies of diet, genes, and drugs indicate that \u003cstrong\u003edelaying one age-related disease probably staves off others\u003c\/strong\u003e. That's because aging itself is the common risk factor. The authors explain that at least a dozen molecular pathways seem to \"set the pace of physiological ageing\" — the biological clocks that determine how quickly our bodies accumulate damage.\u003c\/p\u003e\n\u003cp\u003eThis has led researchers to coin an important term: \u003cstrong\u003ehealthspan\u003c\/strong\u003e — the number of years lived without chronic, age-related disease. Extending lifespan, they argue, is only worthwhile if it also extends healthspan.\u003c\/p\u003e\n\n\u003ch2 id=\"animal-studies\"\u003eWhat Animal Studies Have Taught Us\u003c\/h2\u003e\n\u003cp\u003eDecades of animal research have shown that aging can be deliberately slowed. The authors highlight several striking findings:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRestricting calorie intake\u003c\/strong\u003e in mice, or introducing mutations in nutrient-sensing pathways, can extend lifespans by as much as \u003cstrong\u003e50%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eThese so-called \"Methuselah mice\" are more likely than control mice to die \u003cem\u003ewithout\u003c\/em\u003e any apparent disease.\u003c\/li\u003e\n  \u003cli\u003ePost-mortem examinations reveal that tumors, heart problems, neurodegeneration, and metabolic disease are generally reduced or delayed in long-lived mice.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn other words, extending lifespan in animals also appears to increase healthspan. The diseases of old age are not randomly scattered — they seem to share an underlying engine, and slowing that engine slows everything at once.\u003c\/p\u003e\n\u003cp\u003eDr. Seals and Dr. Melov add that genetic and pharmacological manipulations can increase life span in worms, flies, and rodents, with some evidence that these manipulations also increase \u003cem\u003ehealthy\u003c\/em\u003e lifespan. A key study cited in this context is the 2009 work by Harrison and colleagues in \u003cem\u003eNature\u003c\/em\u003e, which showed that the drug rapamycin extended lifespan in mice.\u003c\/p\u003e\n\n\u003ch2 id=\"malleable\"\u003eWhy Aging Is Malleable: Evidence from Humans\u003c\/h2\u003e\n\u003cp\u003eThe million-dollar question: do these animal findings apply to people? The authors say the evidence strongly suggests yes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFirst, the biology is shared.\u003c\/strong\u003e Longevity pathways identified in model organisms \"seem to be conserved in humans and can be manipulated in similar ways.\" Genetic surveys of centenarians point to hormonal and metabolic systems as key players in extreme longevity, consistent with what animal studies predict (Barzilai and colleagues, 2010).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSecond, long-term calorie restriction in humans\u003c\/strong\u003e produces \"drastic metabolic and molecular changes\" — particularly in inflammatory and nutrient-sensing pathways — that make people resemble younger individuals. Mice engineered to have reduced signaling in these pathways live longer; humans with similar mutations have lower rates of cancer and diabetes. One striking example comes from a 2011 study by Guevara-Aguirre and colleagues, who studied people with growth hormone receptor mutations and found them largely protected from cancer and diabetes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThird, real-world examples abound.\u003c\/strong\u003e The commentary includes a photo of Fauja Singh, who at age 100 was preparing for Britain's Edinburgh Marathon in 2011. It also notes that groups practising strict healthy lifestyles — such as the Seventh-day Adventists, many of whom follow a mostly vegetarian diet — \"frequently enjoy good health until near the end of life.\"\u003c\/p\u003e\n\u003cp\u003eThe conclusion is direct and hopeful: \u003cstrong\u003e\"The rate of ageing, it seems, is malleable, not fixed.\"\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ch2 id=\"drugs-diets\"\u003eDrugs and Diets on the Horizon\u003c\/h2\u003e\n\u003cp\u003eSeveral molecular pathways that increase longevity in animals are already affected by approved and experimental drugs. The authors walk through the most promising candidates:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRapamycin\u003c\/strong\u003e — a drug already used to treat cancer and prevent organ rejection. It extends lifespan in mice and worms by muting the \u003cstrong\u003emTOR pathway\u003c\/strong\u003e, which regulates everything from protein synthesis to cell proliferation and survival.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSirtuin activators\u003c\/strong\u003e — the sirtuin proteins, involved in a wide range of cellular processes, are activated by naturally occurring compounds such as \u003cstrong\u003eresveratrol\u003c\/strong\u003e (found in red wine). These compounds extend lifespan in metabolically abnormal obese mice.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMetformin\u003c\/strong\u003e — a common diabetes drug. It mimics changes observed in animals fed calorie- and protein-restricted diets.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFasting\u003c\/strong\u003e — triggers cellular responses that boost stress resistance and reduce oxidative damage and inflammation. In rodents, fasting protects against diabetes, cancer, heart disease, and neurodegeneration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe authors emphasize that \"a plethora of natural and synthetic molecules affect pathways that are shared by ageing, diabetes and metabolic syndrome.\" In other words, the drugs we already use for metabolic diseases may have anti-aging effects waiting to be tested.\u003c\/p\u003e\n\u003cp\u003eThey stress, however, that these are leads — not yet proven treatments for humans. The point of their commentary is to urge that these leads be moved into rigorous clinical trials.\u003c\/p\u003e\n\n\u003ch2 id=\"demographics\"\u003eThe Demographic Challenge Ahead\u003c\/h2\u003e\n\u003cp\u003eThe urgency comes from the numbers. The article includes a chart based on United Nations projections showing the global population aged over 60 climbing from roughly half a billion in 1950 to an estimated \u003cstrong\u003e2.5 billion by 2050\u003c\/strong\u003e — with developing countries accounting for the majority of that growth.\u003c\/p\u003e\n\u003cp\u003eOther key projections highlighted in the article:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe number of people over age 80 will \u003cstrong\u003etriple globally by 2050\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eThe number of people aged over 60 in 2050 is projected to be \u003cstrong\u003efive times\u003c\/strong\u003e what it was in 1950.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe authors warn that without interventions to slow aging, this demographic shift could result in \"a demographic crisis of increased disability and escalating health-care costs.\" Every year of additional healthspan, they argue, would relieve pressure on both individuals and health systems.\u003c\/p\u003e\n\n\u003ch2 id=\"funding\"\u003eA Major Roadblock: Funding and Focus\u003c\/h2\u003e\n\u003cp\u003eSo why haven't these insights transformed medicine already? The authors are blunt: scientists are not set up to capitalize on these leads.\u003c\/p\u003e\n\u003cp\u003eThe numbers tell the story. The Division of Aging Biology at the US National Institute on Aging receives \u003cstrong\u003eless than 1% of the National Institutes of Health's (NIH) budget\u003c\/strong\u003e — even though it supports research into the mechanisms underlying most disabilities and chronic diseases. Most grants focus on diseases of specific systems (such as Alzheimer's), and most study sections are not designed to evaluate multidisciplinary research on healthspan. The situation is similar in Europe and Japan.\u003c\/p\u003e\n\u003cp\u003eThere are also communication gaps:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eClinicians do not realize how much is understood about the molecular mechanisms of aging and its broad effects on disease.\u003c\/li\u003e\n  \u003cli\u003eLaboratory researchers are naive about the clinical implications of side effects or overdoses.\u003c\/li\u003e\n  \u003cli\u003eResearchers of all stripes focus too much on easing or reversing the progression of diseases — rather than preventing them by targeting aging.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe authors also point to a deeper structural problem: \u003cstrong\u003eeconomic incentives in both biomedical research and health care reward treating diseases more than promoting health.\u003c\/strong\u003e They note the launch of a few anti-aging biotech companies, such as Calico (created in 2013 by Google), as promising — but insist that public money must be invested in extending healthy lifespan by slowing aging. \"Otherwise,\" they warn, \"we will founder in a demographic crisis.\"\u003c\/p\u003e\n\u003cp\u003eOne more provocative suggestion: gerontologists should work with people who are middle-aged or even younger, not just the elderly — because the best time to slow aging may be decades before diseases appear.\u003c\/p\u003e\n\n\u003ch2 id=\"functional-tests\"\u003eHow We Measure Aging: The Power of Simple Tests\u003c\/h2\u003e\n\u003cp\u003eBefore we can test anti-aging treatments, we need to measure aging itself. Dr. Seals and Dr. Melov explain that gerontologists and geriatricians have developed batteries of tests to assess declines in physiological function as people age. These tests are simple but remarkably predictive:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe ability of insulin to clear glucose from the blood tracks the risk of diabetes.\u003c\/li\u003e\n  \u003cli\u003eStiffer arteries indicate a future of hypertension and cognitive impairments.\u003c\/li\u003e\n  \u003cli\u003eReduced bone density increases the risk of fracture.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePerhaps most striking: \u003cstrong\u003elife expectancy and the likelihood of disability for people over 65 can be predicted from reductions in grip strength, average walking speed, or the ability to sit and rise from the floor.\u003c\/strong\u003e These findings come from studies such as the 2011 \u003cem\u003eJAMA\u003c\/em\u003e paper by Studenski and colleagues, which showed that gait speed predicts survival in older adults.\u003c\/p\u003e\n\u003cp\u003eRegulatory authorities in the United States and the European Union are already considering using combinations of these physical-performance tests to evaluate the effectiveness of drugs in clinical trials for age-related disorders — including sarcopenia (the muscle-wasting condition that affects many older adults).\u003c\/p\u003e\n\u003cp\u003eIn other words: your doctor's simple questions about how fast you walk and how easily you get up from a chair are not trivial. They are validated measures of biological aging.\u003c\/p\u003e\n\n\u003ch2 id=\"the-gap\"\u003eThe Gap: What's Missing in Animal Studies\u003c\/h2\u003e\n\u003cp\u003eHere's the problem: while human researchers have these functional tests, animal researchers mostly do not. In 2004, the US National Institute on Aging launched a programme to test strategies that extend lifespan in mammals. Multiple facilities are funded to assess the same parameters in several mouse strains under standardized conditions. But the authors note a glaring flaw: \u003cstrong\u003emost measurements occur only after the animals die.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFew studies track declines in living animals — thinning bones, hearts pumping less efficiently, or sluggishness in cognitive tasks. The first thorough paper on evaluating cardiovascular function in ageing mice was published barely five years before this commentary (Dai and colleagues, \u003cem\u003eCirculation\u003c\/em\u003e, 2009).\u003c\/p\u003e\n\u003cp\u003eThis matters because animals have \"physiological redundancies\" — manipulating a gene or signaling pathway does not necessarily change the function of an organ or organism. A drug that slows aging should slow declines in several organ systems, but few laboratories can measure this in animals.\u003c\/p\u003e\n\u003cp\u003eEven when animal studies do assess function, the conditions often have little relevance to human aging:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eExperiments on whether a drug improves cardiac function typically use \u003cstrong\u003eyoung mice\u003c\/strong\u003e whose hearts have been purposely injured — rather than old mice with naturally aged hearts.\u003c\/li\u003e\n  \u003cli\u003eTo study obesity, mice are fed diets of up to \u003cstrong\u003e70% fat\u003c\/strong\u003e, with high proportions of trans and saturated fats — diets that bear little resemblance to typical human diets.\u003c\/li\u003e\n  \u003cli\u003eEffects of inflammation are induced with molecules like \u003cstrong\u003elipopolysaccharide\u003c\/strong\u003e at concentrations that would never be observed in normal physiology.\u003c\/li\u003e\n  \u003cli\u003eDamage from oxidative stress — which accumulates over years in humans — is rapidly induced with toxic chemicals such as \u003cstrong\u003eparaquat\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eEach of these models has its place in science, the authors say, but they are poor mimics of human aging. Translational studies — studies designed to bridge animal and human research — must be different.\u003c\/p\u003e\n\n\u003ch2 id=\"better-tools\"\u003eBuilding Better Tools to Track Aging\u003c\/h2\u003e\n\u003cp\u003eWhat would better animal research look like? The authors offer specific suggestions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFirst, track the same animals as they age.\u003c\/strong\u003e Researchers need new methods to characterize function — particularly to follow mice before and after interventions, using imaging tools and minimally invasive techniques. They should measure parameters such as blood pressure, metabolic rate, cardiac output, and kidney filtration — both at the animals' normal resting state and in response to common physiological challenges, such as running on an exercise wheel or completing a maze.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSecond, prioritize motor and cognitive functions.\u003c\/strong\u003e These are the assessments most likely to be recognized by drug regulators and industry. As in human studies, function should be characterized in several organs and tissues, not just one.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThird, account for variability.\u003c\/strong\u003e Variability among animals increases with ageing, and study designs must accommodate that.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFourth, build more specialized laboratories.\u003c\/strong\u003e One model facility is the Healthspan Assessment Laboratory at the Mayo Clinic in Rochester, Minnesota. It quantifies muscle strength and cognitive impairment, and can measure body composition, metabolic rate, insulin sensitivity, motor coordination, bone density, and exercise capacity. The Buck Institute for Research on Aging in Novato, California — where Dr. Melov works — has established similar resources. The authors say more facilities like these are needed.\u003c\/p\u003e\n\u003cp\u003eThe NIH has already released a set of testing batteries for clinical research — including tests for balance, memory, strength, and perception — designed to make it easier to combine results from different trials. Longitudinal human studies such as the NIH-supported \u003cstrong\u003eHealth, Aging, and Body Composition (Health ABC) Study\u003c\/strong\u003e have collected body scans, health inventories, and physical performance data (such as walking speed) that establish clinically relevant measures of bone density, blood pressure, and motor function.\u003c\/p\u003e\n\u003cp\u003eThe key idea: these same kinds of assessments, adapted for rodents, should be used to determine which of the \u003cstrong\u003ehundreds of pharmacological compounds and nutritional interventions\u003c\/strong\u003e shown to slow the effects of aging in model organisms deserve to advance to human trials.\u003c\/p\u003e\n\n\u003ch2 id=\"roadmap\"\u003eRecommendations: A Roadmap Forward\u003c\/h2\u003e\n\u003cp\u003eThe authors close their essays with a concrete roadmap for accelerating the science of healthy aging.\u003c\/p\u003e\n\u003cp\u003eDr. Fontana's team recommends:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDesign animal studies to better mimic human aging.\u003c\/strong\u003e For example, frailty indices are often used in human studies — comparable indices should be developed for mice.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDevelop suitable endpoints for human trials.\u003c\/strong\u003e Animal work suggests many candidate biomarkers, such as accumulation of molecular damage to DNA, proteins, and lipids from oxidative stress.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCollect biological samples during existing clinical trials.\u003c\/strong\u003e Publicly funded trials — such as one studying whether aspirin can prevent heart attacks and general decline in the elderly — could also collect crucial samples of blood, muscle, and fat for molecular analysis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCreate translational committees.\u003c\/strong\u003e Funding agencies should establish committees of translational scientists to review which markers of biological aging are most consistent between animals and humans, and prioritize the most practical for further assessment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEvaluate biomarkers across a broad age range.\u003c\/strong\u003e Chosen biomarkers should be assessed in clinical studies of patients already being treated with drugs that increase lifespan in animal models. Assessments must also be developed for dietary or other non-drug interventions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChange the mindset.\u003c\/strong\u003e The most important change is cultural: reward preventing disease and promoting health, not just treating sickness.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eDr. Seals and Dr. Melov add:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpand functional assessments in model organisms\u003c\/strong\u003e — especially rodents — using tests already established in humans.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRequire basic and clinical researchers to collaborate more.\u003c\/strong\u003e At the NIH, basic and clinical research relating to the biology of aging are administered in separate programmes — a structural barrier to translation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRethink training and funding.\u003c\/strong\u003e The entire ageing-research community must rethink how its members communicate, interact, are trained, and are funded.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThe authors acknowledge that the need for this kind of \"crosstalk\" in aging research has been stated frequently before — \"with little effect.\" But they believe the development of standardized functional assessments that extend from model organisms to human populations may finally make it happen.\u003c\/p\u003e\n\n\u003ch2 id=\"for-patients\"\u003eWhat This Means for Patients Today\u003c\/h2\u003e\n\u003cp\u003eIt's important to be clear about what this commentary does — and does not — say for patients right now.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat it does say:\u003c\/strong\u003e The current tools for extending healthy life — better diets and regular exercise — are effective. But there is room for improvement, especially in personalizing treatments. The evidence that healthy lifestyle habits matter is strong: the Seventh-day Adventists and other groups who maintain strict healthy lifestyles \"frequently enjoy good health until near the end of life.\"\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWhat it does not say:\u003c\/strong\u003e The article does \u003cem\u003enot\u003c\/em\u003e recommend that patients start taking rapamycin, metformin, or resveratrol to slow aging. These are research leads, not proven treatments. The authors explicitly call for rigorous clinical trials to determine which interventions work in humans — and at what doses, in which people, and with what side effects.\u003c\/p\u003e\n\u003cp\u003eThere is also a strong emphasis on prevention starting earlier in life. The authors suggest gerontologists should work with people who are middle-aged or even younger — because aging is a lifelong process, and waiting until diseases appear may be waiting too long.\u003c\/p\u003e\n\u003cp\u003eFor older adults, the practical takeaways are straightforward:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eYour functional abilities — grip strength, walking speed, balance — are meaningful measures of health, and they can be improved with exercise.\u003c\/li\u003e\n  \u003cli\u003eDiet matters at every age; calorie restriction and fasting are active areas of research, but should only be undertaken with medical supervision.\u003c\/li\u003e\n  \u003cli\u003eParticipating in clinical research, when appropriate, can help accelerate the discovery of anti-aging therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations and Open Questions\u003c\/h2\u003e\n\u003cp\u003eThis article is a commentary — an expert perspective — rather than a new clinical study. As such, it has important limitations.\u003c\/p\u003e\n\u003cp\u003eThe animal findings, while impressive and consistent, have not yet been translated into proven human therapies. The 50% lifespan extension seen in calorie-restricted mice does not necessarily translate to the same magnitude of effect in humans, who live much longer and have far more complex biology. The evidence that drugs like rapamycin extend lifespan in animals is strong, but long-term safety and effectiveness data in humans are lacking.\u003c\/p\u003e\n\u003cp\u003eThe biomarkers the authors propose — such as molecular damage from oxidative stress — are promising candidates, not validated endpoints. The field has not yet agreed on what constitutes a meaningful \"anti-aging\" outcome that regulators would accept.\u003c\/p\u003e\n\u003cp\u003eFurthermore, the article was published in 2014. Some of the funding figures and institutional structures described may have changed since then. The field of geroscience has grown considerably, and some of the recommendations (such as standardized functional assessments in animals) have been partially adopted. However, the core argument — that we should target aging itself rather than individual diseases — remains highly relevant and actively debated.\u003c\/p\u003e\n\u003cp\u003eFinally, the authors themselves note that many unanswered questions remain: Which pathways are most important in humans? What are the side effects of long-term interventions? How do we personalize anti-aging treatments? These questions can only be answered through the clinical trials they advocate.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eCan we slow down aging? What does the research say?\u003c\/h3\u003e\n\u003cp\u003eStudies in animals, human genetics, and very long-lived people suggest aging is not fixed and can be slowed. However, these are research findings, not yet proven treatments. Scientists are calling for rigorous clinical trials to test anti-aging interventions in humans, but no drug is currently recommended for slowing aging.\u003c\/p\u003e\n\u003ch3\u003eWhat is healthspan and why does it matter?\u003c\/h3\u003e\n\u003cp\u003eHealthspan is the number of years lived without chronic age-related disease, such as cancer, heart disease, or diabetes. Researchers argue that extending lifespan is only worthwhile if it also extends healthspan. Current medicine treats diseases one at a time, but aging itself is a common risk factor for many conditions.\u003c\/p\u003e\n\u003ch3\u003eHow can I measure my biological age or aging?\u003c\/h3\u003e\n\u003cp\u003eSimple functional tests are surprisingly predictive. Grip strength, walking speed, and the ability to sit and rise from the floor can predict disability and survival in people over 65. Stiffer arteries and reduced bone density also indicate aging. These measures are used in research and can be improved with exercise.\u003c\/p\u003e\n\u003ch3\u003eWhat lifestyle habits are effective for healthy aging?\u003c\/h3\u003e\n\u003cp\u003eBetter diets and regular exercise are effective, according to the article. Groups like Seventh-day Adventists, who follow strict healthy lifestyles with mostly vegetarian diets, frequently enjoy good health until near the end of life. Calorie restriction and fasting are active research areas but should only be done with medical supervision.\u003c\/p\u003e\n\u003ch3\u003eWhy is treating diseases one at a time failing older adults?\u003c\/h3\u003e\n\u003cp\u003eBecause aging comes as a package: over 70% of people over 65 have two or more chronic conditions at once. Treating heart failure, cancer, and diabetes separately ignores that aging is the common risk factor. Delaying one age-related disease probably staves off others, so targeting aging itself may be more effective.\u003c\/p\u003e\n\u003ch3\u003eWhat should patients do today based on this research?\u003c\/h3\u003e\n\u003cp\u003eThere are no proven anti-aging medications yet. Focus on healthy diet and exercise, since functional abilities like walking speed and grip strength are meaningful and can improve. Consider participating in clinical research if appropriate. The article does not recommend taking rapamycin, metformin, or resveratrol for aging.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before taking anti-aging drugs like rapamycin or metformin?\u003c\/h3\u003e\n\u003cp\u003eThe article emphasizes that rapamycin, metformin, and resveratrol are research leads, not proven treatments, and it does not recommend that patients start taking them to slow aging. The authors call for rigorous clinical trials to determine which interventions work in humans, at what doses, and with what side effects. A second opinion can help you weigh whether a proposed anti-aging treatment is supported by evidence or still experimental, and whether lifestyle measures like diet and exercise are more appropriate. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published as a two-part Commentary in \u003cem\u003eNature\u003c\/em\u003e (Volume 511, pages 405–407, 24 July 2014).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e tactics to stamp out herbicide\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eLuigi Fontana, MD, PhD — Professor of Medicine and Nutrition, Washington University in St. Louis, Missouri, USA, and Brescia University, Italy.\u003c\/li\u003e\n  \u003cli\u003eBrian K. Kennedy, PhD — Director, Buck Institute for Research on Aging, Novato, California, USA.\u003c\/li\u003e\n  \u003cli\u003eValter D. Longo, PhD — Director, Longevity Institute, University of Southern California, Los Angeles, USA.\u003c\/li\u003e\n  \u003cli\u003eDouglas Seals, PhD — Professor, Department of Integrative Physiology, University of Colorado Boulder, Colorado, USA.\u003c\/li\u003e\n  \u003cli\u003eSimon Melov, PhD — Director of Genomics, Buck Institute for Research on Aging, Novato, California, USA.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on the original commentary published by Macmillan Publishers Limited. Key studies referenced in the original include Fontana, Partridge \u0026amp; Longo (\u003cem\u003eScience\u003c\/em\u003e, 2010), Harrison et al. (\u003cem\u003eNature\u003c\/em\u003e, 2009), Studenski et al. (\u003cem\u003eJAMA\u003c\/em\u003e, 2011), Guevara-Aguirre et al. (\u003cem\u003eScience Translational Medicine\u003c\/em\u003e, 2011), and Longo \u0026amp; Mattson (\u003cem\u003eCell Metabolism\u003c\/em\u003e, 2014). This translation is provided for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your diet, medications, or exercise routine.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47499366695068,"sku":null,"price":0.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com\/pt\/products\/can-we-slow-down-aging-inside-the-push-to-extend-healthspan","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}